Enliven Therapeutics, Inc. (ELVN)
After hours:
| Previous close | 20.44 |
| Open | 20.27 |
| Bid | 20.06 x 100 |
| Ask | 20.24 x 100 |
| Day's range | 19.78 - 20.47 |
| 52-week range | 9.80 - 26.00 |
| Volume | |
| Avg. volume | 355,165 |
| Market cap | 961.429M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.75 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.67 |
GlobeNewswireEnliven Therapeutics to Present at Two Upcoming Investor Conferences
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 5Time: 8:30 a.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside C
- GlobeNewswire
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients Strong balance sheet with $321 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focu
Barrons.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.
